Allergan Aesthetics will present eight scientific posters featuring new and long-term evidence across HArmonyCaâ„¢, JUVÉDERM®, SKINVIVEâ„¢ and BOTOX® Cosmetic The latest HArmonyCaâ„¢ ...
New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs ...
In a Phase 2a study, ABBV-466 achieved higher endoscopic remission rates in patients with Crohn's disease than either anti-IL-23 p19 or anti-α4β7 monotherapy at Week 12, the primary ...
AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programs Latest long-term and real-world data with ...
Higher rates of endoscopic remission and ulcer-free endoscopy were observed following subcutaneous SKYRIZI® (risankizumab-rzaa)treatment versus placeboi Results build on previously reported ...
New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints ...
As a highly focused research-driven biopharmaceutical company, AbbVie takes on the toughest health challenges. But we do more than treat diseases - we aim to make a remarkable impact on people's lives ...
NORTH CHICAGO, Ill., Oct. 7, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted two Breakthrough Therapy Designations (BTDs) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results